Skip to main content
NCBI home page
Atencion Primaria logoLink to Atencion Primaria
. 2008 Nov 18;37(2):104–107. [Article in Spanish] doi: 10.1157/13084490

Hiperaldosteronismo primario: ¿debemos plantearnos su detección sistemática en los centros de salud?☆

C Maciá-Bobes a,⁎, A Ronzón-Fernández b, G Castaño-Fernández a, P Botas-Cervero a
PMCID: PMC7668976  PMID: 16527118

The content is available as a PDF (97.2 KB).

Footnotes

☆

Los autores declaran que no existe conflicto de intereses en este artículo.

Bibliografía

  • 1.Ganguly A. Primary aldosteronism. N Engl J Med. 1998;339:1828–1834. doi: 10.1056/NEJM199812173392507. [DOI] [PubMed] [Google Scholar]
  • 2.Mulatero P., Stowasser M., Loh K- C., Fardella C.E., Gordon R.D., Mosso L. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers for five continents. J Clin Endocrinol Metab. 2004;89:1045–1050. doi: 10.1210/jc.2003-031337. [DOI] [PubMed] [Google Scholar]
  • 3.Fardella C.E., Mosso L., Gómez-Sánchez C., Cortés P., Soto J., Gómez L. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile and molecular biology. J Clin Endocrinol Metab. 2000;85:1863–1867. doi: 10.1210/jcem.85.5.6596. [DOI] [PubMed] [Google Scholar]
  • 4.Hiramatsu K., Yamada T., Yukimura Y., Komiya I., Ichikawa K., Ishihara M. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med. 1981;141:1589–1593. [PubMed] [Google Scholar]
  • 5.Pérez Pérez A.J., Casal Rivas M., Courel Barrio M.A., Andrade Olivié M.A. Hiperaldosteronismo primario: aspectos diagnósticos y terapéuticos. Hipertensión. 2002;19:70–79. [Google Scholar]
  • 6.Young W.F., Jr Minireview: primary aldosteronism. Changing concepts in diagnosis and treatment. Endocrinology. 2003;144:2208–2213. doi: 10.1210/en.2003-0279. [DOI] [PubMed] [Google Scholar]
  • 7.Uwaifo GI, Sarlis NJ. Hyperaldosteronism, primary [accedido 17 Mar 2004]. Disponible en: eMedicine.com
  • 8.Young W.F., Jr, Kaplan N.M., Rose B.D. Approach to the patient with hypertension and hypokalemia. UpToDate. 2004;12(3) Last Updated: May 13, 2004. [Google Scholar]
  • 9.Plouin P., Jeunemaitre X. Would wider screening for primary aldosteronism give any health benefits? Eur J Endocrinol. 2004;151:305–308. doi: 10.1530/eje.0.1510305. [DOI] [PubMed] [Google Scholar]
  • 10.Armario P. No es necesario el despistaje del hiperaldosteronismo primario en la gran mayoría de los pacientes hipertensos. Hipertensión. 2004;21:114–118. [Google Scholar]
  • 11.Martínez Debén F.S. Es conveniente el despistaje del hiperaldosteronismo en el paciente hipertenso. Hipertensión. 2004;21:119–126. [Google Scholar]
  • 12.Cuéllar L.A., De Luis L.A., Terroba C. Hiperaldosteronismo primario. Endocrinol Nutr. 2004;51:295–302. [Google Scholar]
  • 13.Laragh J. Laragh’s lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens. 2001;14:491–503. doi: 10.1016/s0895-7061(01)02097-0. [DOI] [PubMed] [Google Scholar]
  • 14.Fukudome Y., Fujii K., Arima H., Ohya Y., Tsuchihashi T., Abe Y. Discriminating factors for recurrent hypertension in patients with primary aldosteronism after adrenalectomy. Hypertens Res. 2002;25:11–18. doi: 10.1291/hypres.25.11. [DOI] [PubMed] [Google Scholar]
  • 15.Sawka A.M., Young W.F., Jr, Thompson G.B., Grant C.S., Farkey D.R., Leibson C. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med. 2001;135:258–261. doi: 10.7326/0003-4819-135-4-200108210-00010. [DOI] [PubMed] [Google Scholar]
  • 16.Stier C.T., Jr, Chander P.N., Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev. 2002;10:97–107. doi: 10.1097/00045415-200203000-00008. [DOI] [PubMed] [Google Scholar]
  • 17.Pitt B., Remme W.J., Cody R., Castaigne A., Pérez A., Palensky J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–717. doi: 10.1056/NEJM199909023411001. [DOI] [PubMed] [Google Scholar]
  • 18.Pitt B., Remme W.J., Zannad F., Neaton J., Martínez F., Roniker B. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321. doi: 10.1056/NEJMoa030207. [DOI] [PubMed] [Google Scholar]
  • 19.Weinberger M.H., Roniker B., Krause S.L., Weiss R.J. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15:709–716. doi: 10.1016/s0895-7061(02)02957-6. [DOI] [PubMed] [Google Scholar]
  • 20.Lim P.O., Young W.F., Jr, MacDonald T.M. A review of the medical treatment of primary aldosteronism. J Hypertens. 2001;19:353–361. doi: 10.1097/00004872-200103000-00001. [DOI] [PubMed] [Google Scholar]
  • 21.Gordon R.D. The challenge of more robust and reproducible methodology in screening for primary aldosteronism. J Hypertens. 2004;22:251–255. doi: 10.1097/00004872-200402000-00006. [DOI] [PubMed] [Google Scholar]
  • 22.Mulatero P., Rabbia F., Milan A., Paglieri C., Morello F., Chiandusi L. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension. 2002;40:897–902. doi: 10.1161/01.hyp.0000038478.59760.41. [DOI] [PubMed] [Google Scholar]
  • 23.Gallay B.J., Ahmad S., Xu L., Toivola B., Davidson R.C. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis. 2001;37:699–705. doi: 10.1016/s0272-6386(01)80117-7. [DOI] [PubMed] [Google Scholar]
  • 24.Rossi E., Regolisti G., Negro., Sani C., Davoli S., Perazzoli F. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens. 2002;15:896–902. doi: 10.1016/s0895-7061(02)02969-2. [DOI] [PubMed] [Google Scholar]
  • 25.Ferrari P., Shaw S.G., Nicod J., Saner E., Nussberger J. Active rennin versus plasma renin activity to define aldosterone ratio for primary aldosteronism. J Hypertens. 2003;22:377–381. doi: 10.1097/00004872-200402000-00023. [DOI] [PubMed] [Google Scholar]
  • 26.Schwartz G.L., Chapman A.B., Boerwinkle E., Kisabeth R.M., Turner S.T. Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin Chem. 2002;48:1919–1923. [PubMed] [Google Scholar]
  • 27.Montori V.M., Young W.F., Jr Uso del cociente concentración plasmática de aldosterona: actividad plasmática de la renina como prueba de detección para el aldosteronismo primario. Una revisión sistemática de la bibliografía. Clin Endocrinol Metabol N Am (ed. esp.) 2002;3:601–615. [Google Scholar]
  • 28.Weinberger M.H., Fineberg N.S. The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Intern Med. 1993;153:2125–2130. [PubMed] [Google Scholar]
  • 29.Martínez-Debén F.S., Touceda D.S., Fernández F., Castro R., Paredes M.L. Valores de normalidad del cociente aldosterona/actividad de renina plasmática en población española normotensa. Hipertensión. 2002;19(Supl 2):21. [Google Scholar]
  • 30.Hirohara D., Nombra K., Kamoto T., Ujihara M., Takano K. Performance of the basal aldosterone to renin action and the of rennin stimulation test by furosemide and upright posture in screening for aldosterone-producing adenoma in low rennin hypertensives. J Endocrinol Metab. 2001;86:4292–4298. doi: 10.1210/jcem.86.9.7867. [DOI] [PubMed] [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES